Lumida
/OFIX
⌘K
Orthofix Medical Inc

Orthofix Medical Inc

OFIX
$11.58USD↓-2.61%-0.31 today

MARKET CAP

468.1M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$11 – $12

52W RANGE

$9
$17

AI Summary

Stalk
TrimMedium

The asset remains in a Stage 4 decline with confirmed lower highs and lower lows under declining EMAs. Price has been rejected at the 9/20 EMA band repeatedly, reinforcing a medium-term bearish bias. Oversold status does not grant mean-reversion permission, and short-term timing is neutral. Execution should be deferred into future rally attempts into EMA resistance rather than sold immediately. A Trim is recommended to seek a better entry point on a bounce into the EMAs.

  • ↑Virada spinal system launch expected to enhance surgical efficiency and penetrate $2B US pedicle screw market.
  • ↑Q1 net sales $196.4M, up 3% YoY; top 30 distributors drove 27% growth.
  • ↓Medicare reimbursement reversals and FDA reclassification risk could shrink revenue.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

OrthoFix Medical Inc. (NASDAQ: OFIX) is a leading global medical technology company dedicated to advancing orthopedic and spine solutions, focusing on innovative products for bone growth therapies, spinal fixation, and limb reconstruction. With a strong operational presence in the United States and a commitment to improving patient outcomes through technological advancements, OrthoFix is well-positioned to capitalize on evolving healthcare demands and innovations, particularly in surgical procedures.

Bull says

  • ↑Virada spinal system launch expected to enhance surgical efficiency and penetrate $2B US pedicle screw market.
  • ↑Q1 net sales $196.4M, up 3% YoY; top 30 distributors drove 27% growth.
  • ↑Cash balance $120.9M funds operations and strategic initiatives.
  • ↑Gross margin expanded to 70.7% (+40bps YoY); EBITDA $9.7M; 2026 sales guidance $850–860M (+5.5%).
  • ↑Strong book-to-price ratio and high institutional ownership indicate solid valuation support.
  • ↑Optimized distributor network and backlog momentum support near-term market penetration.

Bear says

  • ↓Medicare reimbursement reversals and FDA reclassification risk could shrink revenue.
  • ↓Price decrease at a major account lowered margins and sales.
  • ↓Distributor transition inefficiencies may trigger temporary revenue shortfalls.
  • ↓Weak earnings yield and profitability factors signal fundamental inefficiencies.
  • ↓Legal settlements risk cash flow and increase uncertainty.
  • ↓Negative growth revisions and small size limit scale advantages.

Investment themes with OFIX

Medical Devices↑ +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026neutral

Transcript signals

Bull points

  • total global net sales of 196.4 million increased 3% year over year
  • continued growth from our top 30 distributors in the U.S.
  • Therapeutic Solutions BGT net sales were $57.8 million, up 5%, as we continued to outperform the market.

Bear points

  • timing of certain international stocking orders benefited Q1 results by approximately $2 million
  • U.S. performance was flat, largely due to the timing of Oscar capital sales.
  • While progress is evident, we are still early in the year and remain focused on converting improved activity levels into consistent above-market profitable growth.
Read full transcript analysis ›